Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
83.48
+0.48 (+0.58%)
Streaming Delayed Price
Updated: 9:55 AM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
March 29, 2022
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country
Via
Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
March 29, 2022
Pre-open movers
Via
Benzinga
Biotech Funds and ETFs Continue to Lag
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld
March 24, 2022
EMA's human medicines committee (CHMP) has
Via
Benzinga
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
March 24, 2022
Via
Benzinga
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
March 24, 2022
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters
March 23, 2022
European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,
Via
Benzinga
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
March 23, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 1.6% on an annualized basis producing an average annual return of 15.33%. Currently, AstraZeneca has...
Via
Benzinga
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
March 21, 2022
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.
Via
Benzinga
Morning Brief: Top Stories Dominating Financial Media on Monday, March 21
March 21, 2022
CNBC Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant,...
Via
Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
March 21, 2022
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases.
Via
Benzinga
AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows
March 21, 2022
AstraZeneca Plc's (NASDAQ: AZN) antibody-based cocktail to prevent and treat COVID-19 retained
Via
Benzinga
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT
March 18, 2022
Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company
Via
Benzinga
Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron
March 17, 2022
Via
Benzinga
AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai
March 17, 2022
Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris...
Via
Benzinga
AstraZeneca's COVID-19 Therapy Approved In Britain As Preventive Option
March 17, 2022
Britain's Medicines and Healthcare products Regulatory Agency (MHRA)
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody
March 16, 2022
Via
Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
March 16, 2022
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren&
Via
Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
March 16, 2022
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future.
Via
Benzinga
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
March 15, 2022
Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Hopes For A Peace Accord
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition
March 14, 2022
The FDA has declined to approve AstraZeneca Plc's (NASDAQ: AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a...
Via
Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
March 14, 2022
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...
Via
Benzinga
Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead
March 10, 2022
We're taking a gander at more companies that could follow Amazon's (AMZN) lead with potential upcoming stock splits in 2022.
Via
InvestorPlace
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
March 07, 2022
Gilead's Trodelvy had mixed test results in patients with breast cancer.
Via
Investor's Business Daily
Merck (MRK) Outperforms Industry, What's In Store For 2022?
March 07, 2022
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.
Via
Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
March 03, 2022
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.